Psy45 - Budget Impact Analysis of the Patient Blood Management From a French National Payer and Hospital Perspectives in France

Abstract

inhibitor have been calculated over 3-years and compared for the two scenario analyses. Emicizumab price was assumed equal to 210.2V/mg in order to have the same annual costs of aPCC prophylaxis. Sensitivity analyses were performed to identify the price scenario where emicizumab reported a neutral budget impact. RESULTS: Based on actual treatment utilization data in Italy, the model estimated a 3-years overall cost of 368,839V mln in all hemophilic patients with inhibitor (mean cost per patient/ year ¼723,213V). Assuming a possible switch also from less expensive regimens (on-demand and high dose rFVIII prophylaxis) to emicizumab prophylaxis, a budget impact of +38.5Vmln (+10%) was reported over three-years. Changing emicizumb price, a neutral budget impact was obtained at 157.6V/mg (-25% of basecase price). CONCLUSIONS: The budget estimation is sensitive to emicizumab price. A neutral budget impact can be obtained if emicizumab price was set to 157.6V/mg. Below the neutral price, emicizumab prophylaxis use could save millions of euro. For example, an expected budgetary saving of 39.0V mln was estimated assuming a price of 105.10V/mg.